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Abstract
BACKGROUND: Pimavanserin is a 5-HT2A receptor inverse 
agonist/antagonist and is approved in the United States for 
the treatment of hallucinations and delusions associated with 
Parkinson’s disease psychosis.  
OBJECTIVE: Evaluate the efficacy of pimavanserin on 
symptoms of psychosis in patients with Alzheimer’s disease 
(AD).
DESIGN: Randomized, double-blind, placebo-controlled trial.
SETTING: Nursing home residents.PARTICIPANTS: Patients 
with AD psychosis.
INTERVENTIONS: Pimavanserin 34 mg or placebo daily for 12 
weeks.
MEASUREMENTS: The primary endpoint was mean change 
from baseline at Week 6 on the Neuropsychiatric Inventory-
Nursing Home Version psychosis score (NPI-NH-PS). In the 
prespecified subgroup analysis, the mean change in NPI-NH-PS 
and the responder rates among those with baseline NPI-NH-PS 
≥12 were evaluated. 
RESULTS: Of 181 patients randomized (n=90 pimavanserin; 
n=91 placebo), 57 had baseline NPI-NH-PS ≥12 (n=27 
pimavanserin; n=30 placebo). In this severe subgroup, large 
treatment effects were observed (delta=-4.43, Cohen’s d=-0.73, 
p=0.011), and ≥30% improvement was 88.9% vs. 43.3% (p<0.001) 
and ≥50% improvement was 77.8% vs. 43.3% (p=0.008) for 
pimavanserin and placebo, respectively. The rate of adverse 
events (AEs) in the severe subgroup was similar between 
treatment groups, and urinary tract infection, fall, and agitation 
were most frequent. Serious AEs was similar with pimavanserin 
(17.9%) and placebo (16.7%) with fewer discontinuations due 
to AEs with pimavanserin (7.1%) compared to placebo (10.0%). 
Minimal change from baseline occurred for the mean MMSE 
score over 12 weeks. 
CONCLUSIONS: Pimavanserin demonstrated significant 
efficacy in AD psychosis in patients with higher baseline 
severity of psychotic symptoms (NPI-NH-PS ≥12). Treatment 
with pimavanserin showed an acceptable tolerability profile.  
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Worldwide, over 40 million people have Alzheimer’s disease (AD) or related dementia (1). Neuropsychiatric symptoms 
such as psychosis including delusions and visual 
hallucinations occur in 25% to 50% of individuals with 
AD (2, 3). In addition to occurring in patients with AD, 
psychosis also occurs in patients with other dementias 
of a wide variety of etiologies (4). The occurrence of 
psychotic symptoms in people with AD places a 
substantial burden on patients with AD, family, and 
caregivers (1). Patients experiencing psychotic symptoms 
have more rapid cognitive and functional decline, 
increased co-morbidity with other neuropsychiatric 
symptoms including depression and agitation, have 
higher rates of nursing home admissions, and greater 
treatment-related mortality (5, 6). An increased severity 
of psychotic symptoms may be associated with increased 
disease severity and duration and may be a negative 
predictor of the overall disease outcomes (7). 
Although antipsychotics are commonly used to treat 
psychosis in patients with dementia and Parkinson’s 
disease (8, 9), randomized, controlled trials of 
antipsychotics indicate modest efficacy for the treatment 
of psychosis (10, 11). Meta-analyses of antipsychotic use 
in patients with AD suggest a small effect size (<0.2) 
from clinical trials (12, 13), and their use is associated 
with cognitive decline as well as increased rates of stroke, 
bronchopneumonia, pulmonary embolism, and mortality 
(14, 25). However, until recently, no drug was approved 
for the treatment of the symptoms of psychosis associated 
with a neurodegenerative disease.
In 2016, based on the results from controlled clinical 
studies (16, 17) pimavanserin was approved in the 
United States for the treatment of hallucinations and 
delusions associated with Parkinson’s disease psychosis. 
Pimavanserin, is a selective 5-hydroxytryptamine (HT)2A 
receptor inverse agonist/antagonist with substantively 
lower affinity for the 5-HT2C receptor and negligible 
affinity for dopaminergic, muscarinic, histaminergic, or 
adrenergic receptors (18). Results from previous studies 
suggested that activity at the 5-HT2A receptor could also 
provide benefits for AD psychosis (19) and formed the 
basis for a randomized, double-blind, placebo-controlled 
Phase 2 study where pimavanserin demonstrated 
significant efficacy in AD patients with psychosis (20). 
Unlike atypical antipsychotics, pimavanserin did not 
have a negative impact on cognitive function (20, 21). 
In addition, no negative effects on motor function were 
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observed with pimavanserin, and the incidence and types 
of adverse events were comparable with pimavanserin 
and placebo.
This report describes the efficacy and tolerability of 
pimavanserin and placebo in a prespecified subgroup 
of patients with severe psychosis associated with 
Alzheimer’s disease as classified by the cut-off score of 
≥12 on the Neuropsychiatric Inventory-Nursing Home 
Version (NPI-NH) psychosis score (22, 23).
Methods
Primary results from this Phase 2 study were 
previously reported (20). In brief, the study was 
conducted at King’s College London in a network of 
nursing homes across the United Kingdom. An 
Independent Data Monitoring Ethics Committee 
provided study oversight. The study was conducted 
in accordance with the Declaration of Helsinki and the 
International Council for Harmonisation of Technical 
Requirements for Pharmaceuticals for Human Use; 
Good Clinical Practices; and the United States Code 
of Federal Regulations. Ethics Committee approval 
was obtained for the study protocol and informed 
consent form, and patients or their legally authorized 
representative provided informed consent prior to any 
study procedures. 
Study Design
This was a randomized, double-blind, placebo-
controlled study, with the primary efficacy analysis at 
the 6-week time point. Study participants continued 
treatment to 12 weeks with the objective to evaluate 
overall safety, effects on cognition, and assess 
maintenance of effect. Patients were randomized equally 
to pimavanserin 34 mg or placebo once daily, and 
randomization was stratified by baseline Mini-Mental 
State Examination (MMSE) (24) in two levels (MMSE <6 
and MMSE ≥6) and NPI-NH psychosis score in two levels 
(hallucinations and delusions <12 and ≥12).
Patient Selection
Adults ≥50 years of age were eligible if they had 
possible or probable AD as defined by the National 
Institute of Neurological and Communicative Disorders 
and Stroke-Alzheimer’s Disease and Related Disorders 
Association (NINCDS-ADRDA) (25) and satisfying 
criteria for psychosis associated with Alzheimer’s disease 
(26). Patients were required to have psychotic symptoms 
including visual and/or auditory hallucinations and/
or delusions that developed after the diagnosis of AD 
was established and must have been a nursing home 
resident for ≥4 weeks prior to randomization. Further, 
patients were required to be actively experiencing 
psychotic symptoms during the month prior to screening 
that required treatment for psychotic symptoms (26). 
Patients were required to have a score of ≥4 on either 
hallucinations (Frequency × Severity) or delusions 
(Frequency × Severity) of the NPI-NH psychosis 
subscale or a total combined score ≥6 (hallucinations + 
delusions) and have symptoms that required treatment 
with an antipsychotic medication. Treatment with other 
antipsychotics or other centrally acting medications was 
not allowed, and doses of antidepressant and anxiolytic 
drugs had to remain unchanged during the study. Doses 
of an acetylcholinesterase inhibitor (and/or memantine) 
must have been stable for 3 months prior to baseline 
and during the study. Patients were excluded for a 
history of significant psychotic disorders prior to or 
concomitant with the diagnosis of AD, as well as any 
medical condition that could interfere with the conduct of 
the study. 
Study Assessments
The NPI-NH psychosis score (hallucinations + 
delusions) was used to assess psychosis and determine 
the primary outcome. Behavioral symptoms were 
assessed using the NPI-NH Total score, as well as the 
individual behavioral domain scores, and using the 
Cohen-Mansfield Agitation Inventory-Short Form 
(CMAI-SF) (27). Cognitive status was evaluated with the 
MMSE; overall condition was rated with the Alzheimer’s 
Disease Cooperative Study-Clinical Global Impression 
of Change (ADCS-CGIC) (28); and activities of daily 
living (ADL) were evaluated using the Alzheimer’s 
Disease Cooperative Study-ADL instrument (ADCS-
ADL) (29). Safety was assessed from adverse events 
(AEs), physical examinations, clinical laboratory tests, 
electrocardiograms, and vital signs. 
Statistical Analysis
The primary efficacy outcome was change from 
baseline to Week 6 for the NPI-NH psychosis score 
(hallucinations + delusions) for pimavanserin vs. placebo. 
The focus of the prespecified subgroup analysis was 
efficacy assessment for baseline NPI-NH psychosis score 
≥12 on the primary outcome (NPI-NH psychosis score) 
and the responder analysis. 
For the responder analyses, the reported responder 
rates were the observed proportions with a response 
(improvement from baseline) at Week 6, after 
conservatively imputing any missing values as non-
responders. The treatment groups were compared 
using a Cochran-Mantel-Haenszel test, stratified by 
baseline MMSE category (<6 or ≥6). For prespecified 
efficacy outcomes, the analysis model included fixed 
effects of baseline MMSE category (<6 or ≥6), treatment 
(pimavanserin 34 mg or placebo), visit (Days 15, 29, 
43, 64, and 85), treatment-by-visit interaction, and a 
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continuous, fixed covariate of baseline score (except 
for ADCS-CGIC where there is no baseline score). All 
efficacy analyses used the full analysis set (FAS), which 
included all randomized participants who received at 
least one dose of study drug and had both a baseline 
and at least one post-baseline NPI-NH psychosis score 
assessment. All efficacy analyses were conducted using 
2-sided tests at the 5% significance level. Adverse events 
were coded using Medical Dictionary for Regulatory 
Activities (MedDRA) Version 17.0.
Results
In the overall study population, 181 patients were 
randomized to pimavanserin (n=90) and placebo (n=91). 
In the FAS, the group with an NPI-NH psychosis 
score ≥12 (more severe group) comprised 27 patients 
randomized to pimavanserin and 30 randomized 
to placebo. At baseline, demographic and clinical 
characteristics were generally similar between the overall 
population and the more severe subgroup (Table 1). 
However, among patients in the more severe subgroup 
vs. the overall population, mean NPI-NH total, psychosis, 
and agitation/aggression scores were higher, and the 
mean MMSE score was lower, consistent with the overall 
greater severity of illness (Table 1).
In the overall population, the adjusted mean change 
(SE) from baseline to Week 6 (adjusted mean, MMRM 
analysis) for the NPI-NH psychosis score was -3.76 (0.65) 
for pimavanserin and -1.93 (0.63) for placebo (delta = 
-1.84, 95% confidence interval [CI] [-3.64, -0.04] Cohen’s d 
= -0.32, p=0.045).
Among patients with baseline NPI-NH psychosis 
score ≥12, mean baseline scores were 15.3 and 16.7 with 
pimavanserin and placebo, respectively. The mean 
change in NPI-NH psychosis score from baseline to Week 
6 was -10.15 (95% CI: -12.50, -7.80) for pimavanserin 
and -5.72 (95% CI: -8.14, -3.30) for placebo (Figure 1A), 
resulting in a delta of -4.43 (95% CI: -7.81, -1.04) and 
Cohen’s d effect size of -0.73 (p=0.011). 
* Cohen’s d effect size of -0.73 (p=0.011)
Overall, in the more severe subgroup, 81% of patients 
had both hallucinations and delusions at baseline. In 
this subgroup, pimavanserin was superior to placebo 
in treating both hallucinations and delusions with 
significant improvements observed at Week 6 for both 
the NPI-NH hallucinations (p=0.046) and delusions 
(p=0.034) domain scores (Table 2). Significant differences 
between pimavanserin and placebo were not observed for 
other secondary or exploratory outcomes. In the severe 
subgroup, the change for the NPI-NH psychosis score 
Table 1. Baseline demographics and clinical characteristics for the subgroup with NPI-NH psychosis score ≥12 vs. 
overall population
NPI-NH psychosis score  ≥12 Overall Population
Pimavanserin (n=27) Placebo (n=30) Pimavanserin (n=87) Placebo (n=91)
Female, n (%) 22 (81.5) 25 (83.3) 71 (81.6) 73 (80.2)
Age, years a 84.9 (7.4) 85.9 (5.3) 85.6 (7.0) 86.1 (6.0)
White, n (%) 23 (85.2) 29 (96.7) 81 (93.1) 89 (97.8)
BMI, kg/m2 a 24.8 (6.7) 22.2 (5.2) 24.1 (5.1) 23.1 (4.6)
Prior Antipsychotic Usage, n (%) 3 (11.1) 4 (13.3) 10 (11.5) 6 (6.6)
Concomitant SSRI, n (%) 8 (29.6) 8 (26.7) 21 (24.1) 20 (22.0)
Concomitant Anti-dementia Medication, n (%) 9 (33.3) 12 (40.0) 33 (37.9) 40 (44.0)
NPI-NH Total Score (10-domain score) a 49.0 (15.4) 45.8 (20.6)  33.2 (17.7) 32.9 (19.4)
NPI-NH Psychosis Score a 15.3 (4.2) 16.7 (4.5) 9.5 (4.8) 10.0 (5.6)
NPI-NH Agitation/Aggression a 7.1 (3.8) 5.9 (4.2) 4·9 (4.0) 4·5 (3.8)
MMSE a 8.6 (4.8) 9.2 (5.3) 10·3 (5.4) 9·8 (5.0)
MMSE <6, n (%) 7 (28.0) 5 (19.2) 18 (21.4) 15 (17.6)
a Mean (standard deviation); BMI = body mass index; MMSE = Mini-Mental State Examination; NPI-NH = Neuropsychiatric Inventory - Nursing Home Version; SSRI = 
selective serotonin reuptake inhibitor.
Figure 1A. Least square mean change from baseline in 
NPI-NH psychosis score at each study assessment in 
participants with baseline NPI-NH psychosis score ≥12 
(pimavanserin, n=27; placebo, n=30)
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was significantly (Spearman Correlation=0.4571, p<0.001) 
correlated with the ADCS-CGIC score at Week 6. 
Responder Analysis
A responder analysis was conducted of the proportion 
of patients achieving a decrease in the NPI-NH psychosis 
score of ≥20%, ≥30%, ≥50%, ≥75%, and 100% at Week 
6. The proportion with a baseline NPI-NH psychosis 
score ≥12 achieving a response was significantly (p<0.05) 
greater with pimavanserin vs. placebo at all increments 
except for 100% (Figure 1B). 
To enter the study, participants needed to have a score 
of ≥4 on the either hallucinations or delusions domains 
of the NPI-NH psychosis scale or an NPI-NH psychosis 
score ≥6. The baseline score for the severe group was 
15.3 and 16.7 for pimavanserin and placebo, respectively 
(Table 1). At Week 6, 66.7% of pimavanserin patients 
improved to an NPI-NH psychosis score <6 vs. 32.0% 
of placebo patients with a treatment difference of 34.7% 
in favor of pimavanserin. At Week 12, 45.5% of both 
pimavanserin and placebo-treated patients had an NPI-
NH psychosis score <6.
Tolerability
The incidence of adverse events (AEs) was comparable 
for the more severe (score ≥12) subgroup vs. the overall 
population (Table 3). In the pimavanserin group, the 
incidence of aggression was 14.3% in the severe subgroup 
Table 2. Secondary and exploratory outcomes for the subgroup with baseline NPI-NH psychosis score ≥12
Baseline MMRM LS Mean Change 





Pimavanserin Placebo Delta Effect Size p-value
NPI-NH Total Score (10-domain score) 49.04 45.83 -22.64 -14.30 -8.34 -0.45 0.114
NPI-NH Delusions 9.89 9.63 -6.39 -4.06 -2.33 -0.61 0.034
NPI-NH Hallucinations 5.41 7.03 -3.65 -1.78 -1.87 -0.57 0.046
NPI-NH Agitation/Aggression 7.11 5.93 -2.38 -2.12 -0.26 -0.06 0.829
NPI-NH Depression/Dysphoria 3.41 3.10 -1.15 -0.94 -0.21 -0.07 0.799
NPI-NH Anxiety 2.81 2.87 -1.17 -0.32 -0.85 -0.25 0.361
NPI-NH Elation/Euphoria 0.78 1.87 -0.70 -0.92 0.22 0.15 0.606
NPI-NH Apathy/Indifference 4.63 3.43 -2.79 -1.65 -1.13 -0.35 0.212
NPI-NH Disinhibition 3.44 2.63 -0.94 -0.87 -0.08 -0.03 0.925
NPI-NH Irritability/Lability 5.67 4.87 -2.11 -0.49 -1.62 -0.43 0.129
NPI-NH Aberrant Motor Behavior 5.89 4.47 -1.19 -1.19 0.01 0.00 0.996
NPI-NH Sleep/Nighttime Behavior 2.81 3.83 -1.41 -0.85 -0.57 -0.18 0.525
NPI-NH Appetite and Eating Changes 2.41 1.33 -0.64 -0.55 -0.09 -0.03 0.908
ADCS-ADL 15.96 14.93 -0.38 -2.90 2.52 0.36 0.192
ADCS-CGIC - - 3.44 3.76 -0.31 -0.22 0.425
CMAI-SF Total Score 32.33 32.30 -5.22 -3.97 -1.24 -0.14 0.618
CMAI-SF Aggressive Behavior 8.70 8.63 -1.11 -1.02 -0.09 -0.03 0.919
CMAI-SF Physically Nonaggressive Behavior 11.22 10.20 -0.88 -1.16 0.28 0.07 0.801
CMAI-SF Verbally Agitated Behavior 12.41 13.50 -3.23 -1.87 -1.36 -0.34 0.230
Figure 1B. Responder analysis at Week 6 for subgroup 
with NPI-NH psychosis score ≥12 (pimavanserin, n=27; 
placebo, n=30)
Figure 2. Least square mean change from baseline for 
MMSE for Safety Population (pimavanserin, n=90; 
placebo, n=91)
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vs. 10.0% in the overall population, and the incidence of 
agitation was 17.9% and 21.1% in the severe subgroup 
and overall population, respectively. The overall 
incidence of adverse events, serious adverse events, 
and adverse events causing discontinuation as well 
as the incidence of all other individual adverse events 
was similar or lower with pimavanserin in the severe 
subgroup (Table 3). Minimal change from baseline was 
observed for the mean MMSE score in either treatment 
group in the overall study population over 12 weeks of 
treatment (Figure 2). 
Discussion
In the overall population of patients with AD 
psychosis, pimavanserin exhibited efficacy for the 
primary endpoint, NPI-NH psychosis score, at Week 6 
without negative cognitive effects (20). This prespecified 
analysis was conducted in participants with more severe 
psychosis at baseline based on an NPI-NH psychosis 
score ≥12, which represented approximately 30% of 
the overall study population, a population that is at 
critical risk for untoward outcomes. While many baseline 
characteristics were similar between the overall and 
severe populations, the higher baseline scores for the 
NPI-NH total, NPI-NH psychosis score, and agitation/
aggression domain scores along with lower mean MMSE 
score supports the hypothesis that the more severe 
population defined by an NPI-NH psychosis score ≥12 
represents a more impaired group of patients with AD 
psychosis than was represented by the overall population 
and thus in a greater need for suitable pharmacologic 
treatment.
For the primary endpoint of mean change in the 
NPI-NH psychosis score from baseline to Week 6, a 
notably large Cohen’s d effect size of -0.73 was observed 
compared with the effect sizes in the overall population 
(-0.32). In this vulnerable group of patients, the effect 
size was more than two-fold greater than reported in 
the overall study population and more than three-fold 
greater than the effect size of atypical antipsychotics 
reported from meta-analyses in populations of patients 
with dementia-related psychosis (11). Thus, the effect of 
pimavanserin was markedly greater in the prespecified 
subgroup with more severe psychotic symptoms. Even 
more impressive were the results of responder analyses. 
With 88.9% of patients responding to pimavanserin 
treatment with at least a 30% reduction in psychotic 
symptoms and 77.8% responding with at least a 50% 
reduction, the placebo-adjusted responder rates in 
this group were in the range of 35%-45%. In addition, 
a clinically and statistically meaningful reduction in 
severity was observed with pimavanserin for both 
hallucination and delusion domains of the NPI-NH. 
Importantly, these statistically significant findings 
were observed despite a small sample size in the severe 
Table 3. Incidence of adverse events for subgroup with baseline NPI-NH psychosis score ≥12 vs. overall population (Safety 
Population)
Number (%) of Patients
NPI-NH psychosis score  ≥12 Overall Population
Pimavanserin (n=28) Placebo (n=30) Pimavanserin (n=90) Placebo (n=91)
Summary of Adverse Events
Any adverse event 27 (96.4) 30 (100) 88 (97.8) 85 (93.4)
Any serious adverse event 5 (17.9) 5 (16.7) 15 (16.7) 10 (11.0)
Any adverse event causing discontinuation 2 (7.1) 3 (10.0) 8 (8.9) 11 (12.1)
Adverse Events ≥5% Overall Pimavanserin Group
Fall 4 (14.3) 6 (20.0) 21 (23.3) 21 (23.1)
Urinary tract infection 4 (14.3) 9 (30.0) 20 (22.2) 25 (27.5)
Agitation 5 (17.9) 4 (13.3) 19 (21.1) 13 (14.3)
Lower respiratory tract Infection 3 (10.7) 2 (6.7) 13 (14.4) 12 (13.2)
Contusion 4 (14.3) 3 (10.0) 11 (12.2) 14 (15.4)
Aggression 4 (14.3) 2 (6.7) 9 (10.0) 4 (4.4)
Anaemia 2 (7.1) 1 (3.3) 9 (10.0) 8 (8.8)
Blood urea increased 1 (3.6) 3 (10.0) 7 (7.8) 8 (8.8)
Peripheral oedema 1 (3.6) 0 7 (7.8) 2 (2.2)
Cellulitis 1 (3.6) 1 (3.3) 6 (6.7) 3 (3.3)
Anxiety 1 (3.6) 2 (6.7) 5 (5.6) 2 (2.2)
Behavioural and psychiatric symptoms of dementia 1 (3.6) 1 (3.3) 5 (5.6) 2 (2.2)
Blood potassium increased 2 (7.1) 2 (6.7) 5 (5.6) 3 (3.3)
PIMAVANSERIN IN ALZHEIMER’S DISEASE PSYCHOSIS
32
subgroup.
The mean NPI-NH psychosis  score  in  the 
pimavanserin group maintained the effect through 
Week 12 in the more severe subgroup but the difference 
from placebo was not significant due to observed 
improvement in the placebo group from Weeks 6 and 
12. No statistically significant differences were observed 
for other secondary endpoints although a statistically 
significant correlation was observed between the NPI-NH 
psychosis score and the ADCS-CGIC score.
Among patients with AD psychosis, it is reported 
that an increased occurrence of severe psychosis 
is associated with an increased presence of delusions 
and hallucinations as well as symptoms of agitation/
aggression (30). Despite an urgent need for effective 
treatment of these patients, no pharmacological treatment 
is approved for patients with AD psychosis, in particular, 
in patients experiencing severe psychotic symptoms. 
Others have reported an association between the NPI 
score and the duration and severity of psychosis, which 
also was associated with the occurrence of delusions and 
hallucinations (7). In this planned analysis of the severe 
subgroup from the overall study (20), our results are 
consistent with these reports, where we found not only 
a markedly increased NPI-NH total and psychosis score 
among the severe subgroup at baseline, but also a greater 
presence of delusions and hallucinations. In addition, 
baseline factors may have an impact on the magnitude 
of effect with pimavanserin in the AD population. In the 
overall study population, prior antipsychotic drug use 
and increased NPI-NH agitation/aggression scores at 
baseline were associated with greater effect sizes with 
pimavanserin that were significant for prior antipsychotic 
use (p=0.037 and p=0.001, respectively). 
Limitations of this analysis are the small number 
of patients included in the severe subgroup and the 
secondary nature of this subgroup analysis. However, 
patients included in this prespecified analysis were from 
a prospective, randomized, placebo-controlled study, 
and a significant difference was observed for the primary 
outcome, the NPI-NH psychosis score in the overall 
population. The findings of an association between 
dementia-related psychosis and neuropsychiatric 
complaints are consistent with previous reports in 
patients with dementia and suggest that this severe 
population is at greater risk for adverse outcomes that 
require effective treatments (3, 6, 8).
The robust efficacy of pimavanserin in patients 
with more severe psychotic symptoms is relevant to 
the therapeutic benefits of pimavanserin in patient 
populations with AD and psychosis. These results extend 
and confirm the results from the primary analysis in the 
overall population (20) and the results from the subgroup 
analysis of patients with mild dementia in the PDP study 
with pimavanserin (16). These findings coupled with 
the results from other studies of pimavanserin suggest a 
potential role for pimavanserin in treating psychosis in 
patients across a range of neuropsychiatric conditions.
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